世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

詳細検索

詳細検索

世界の調剤薬局市場規模調査および予測:製品別(経口、外用、非経口)、調剤タイプ別(成分変更、投与量変更)、治療用途別(疼痛管理、ホルモン補充療法)、無菌性別(無菌)、エンドユーザー別(小児、成人)、および地域別予測(2025年~2035年)

世界の調剤薬局市場規模調査および予測:製品別(経口、外用、非経口)、調剤タイプ別(成分変更、投与量変更)、治療用途別(疼痛管理、ホルモン補充療法)、無菌性別(無菌)、エンドユーザー別(小児、成人)、および地域別予測(2025年~2035年)


Global Compounding Pharmacy Market Size Study and Forecast by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), and End User (Pediatric, Adult), and Regional Forecasts 20252035

Market Definition, Recent Developments & Industry Trends The compounding pharmacy market encompasses the customized preparation of medications tailored to the specific needs of individual patients... もっと見る

 

 

出版社
Bizwit Research & Consulting LLP
ビズウィットリサーチ&コンサルティング
出版年月
2026年3月24日
電子版価格
US$4,950
シングルユーザライセンス(オンラインアクセス・印刷不可)
ライセンス・価格情報/注文方法はこちら
納期
3-5営業日以内
ページ数
285
言語
英語

英語原文をAI翻訳して掲載しています。


 

サマリー

Market Definition, Recent Developments & Industry Trends
The compounding pharmacy market encompasses the customized preparation of medications tailored to the specific needs of individual patients when commercially available drugs are unsuitable. Compounding pharmacies formulate personalized medications by altering dosage strength, combining active ingredients, removing allergens, or modifying dosage forms. The ecosystem comprises independent and hospital-based compounding pharmacies, outsourcing facilities, raw material suppliers, regulatory bodies, and healthcare providers prescribing customized formulations across multiple therapeutic areas.
In recent years, the market has evolved from a largely fragmented, community-based practice to a more regulated and quality-focused industry segment. Heightened regulatory oversight, particularly for sterile compounding, has led to increased compliance investments and operational standardization. Concurrently, growing demand for personalized medicine, hormone replacement therapy (HRT), pediatric formulations, and pain management solutions has expanded the commercial scope of compounding pharmacies. Technology integration in prescription management, quality control systems, and supply chain traceability is further reshaping the industry landscape. Over the forecast period 2025-2035, the market is expected to demonstrate steady growth, supported by demographic shifts, chronic disease prevalence, and the expanding acceptance of individualized therapeutic regimens.
Key Findings of the Report
- Market Size (2024): USD 13.93 billion
- Estimated Market Size (2035): USD 25.63 billion
- CAGR (2025-2035): 5.70%
- Leading Regional Market: North America
- Leading Segment: Oral formulations under Product segment
Market Determinants
Rising Demand for Personalized Therapeutics
The increasing emphasis on patient-centric care models is a primary growth driver. Standardized, mass-produced medications often fail to address specific patient needs such as allergies, dosage sensitivity, or multi-drug compatibility. Compounding pharmacies offer individualized formulations, creating strong value propositions for healthcare providers seeking optimized therapeutic outcomes. This trend directly enhances prescription volumes and long-term customer retention.
Growth in Chronic Pain and Hormone-Related Conditions
The rising incidence of chronic pain disorders and age-related hormonal imbalances is expanding demand for customized pain management and HRT solutions. Patients requiring alternative dosages or delivery formats often rely on compounded medications, reinforcing steady demand within specialized therapeutic segments. As aging populations grow globally, this structural demand driver is expected to sustain long-term market expansion.
Regulatory Evolution and Compliance Standards
Increased regulatory scrutiny, particularly around sterile compounding practices, has reshaped operational frameworks. While stricter compliance raises costs and entry barriers, it also enhances credibility, improves patient safety, and fosters consolidation among established players. High compliance standards create competitive differentiation and reduce risks associated with quality lapses, strengthening institutional trust in compounding services.
Supply Chain Vulnerabilities and Drug Shortages
Frequent drug shortages in commercial pharmaceutical markets have elevated the importance of compounding pharmacies as alternative suppliers. Ingredient alteration and dosage modification capabilities allow rapid response to unavailable formulations. However, dependency on active pharmaceutical ingredient (API) sourcing and fluctuating raw material prices can constrain margins and operational scalability.
Operational Complexity and Liability Risks
Compounding activities, particularly sterile preparations, involve high procedural complexity and stringent quality control requirements. Liability exposure, recall risks, and compliance costs pose challenges to smaller operators. These constraints may limit expansion capacity but also incentivize consolidation and investment in automation and quality management systems.
Opportunity Mapping Based on Market Trends
Expansion in Sterile Compounding Capabilities
Sterile compounding presents significant growth potential as healthcare institutions increasingly outsource complex injectable preparations.
- Investment in advanced cleanroom infrastructure
- Adoption of automated sterile filling systems
- Partnerships with hospital networks
These initiatives position providers to capture higher-margin institutional contracts and reduce contamination risks.
Specialty Therapeutic Customization
Targeted growth in pain management and HRT reflects broader personalization trends.
- Development of niche formulations
- Integration of digital prescription platforms
- Enhanced collaboration with specialty clinics
Such specialization enables differentiation in a competitive landscape and supports premium pricing strategies.
Pediatric and Geriatric Formulation Innovation
Demographic shifts are creating demand for age-appropriate dosage forms.
- Flavor-masked oral suspensions
- Adjusted-dose capsules
- Non-invasive topical applications
Companies investing in patient-friendly delivery systems can strengthen loyalty among pediatric and geriatric segments.
Technology-Driven Quality and Traceability
Digital quality assurance systems and electronic documentation enhance regulatory compliance and operational efficiency.
- Automated batch tracking
- Data-driven compliance audits
- Inventory optimization platforms
Technology adoption not only reduces risk exposure but also supports scalable growth models.
Key Market Segments
By Product:
- Oral
- Topical
- Parenteral
By Compounding Type:
- Ingredient Alteration
- Dosage Alteration
By Therapeutic Application:
- Pain Management
- HRT
By Sterility:
- Sterile
By End User:
- Pediatric
- Adult
Value-Creating Segments and Growth Pockets
Oral formulations currently dominate the market due to their ease of administration, widespread therapeutic applicability, and cost efficiency. However, parenteral products-particularly sterile injectables-are expected to exhibit accelerated growth as hospital outsourcing increases and regulatory compliance standards strengthen.
Within compounding types, dosage alteration remains foundational to everyday compounding activities, while ingredient alteration is gaining momentum due to allergy considerations and combination therapies. In therapeutic applications, pain management holds a substantial share driven by chronic conditions, whereas HRT is projected to grow steadily, supported by aging demographics and increased awareness.
From an end-user perspective, adult patients represent the larger revenue base today, yet pediatric formulations are emerging as a high-growth pocket given the lack of commercially available child-specific dosages and delivery formats.
Regional Market Assessment
North America
North America leads the global compounding pharmacy market, driven by advanced healthcare infrastructure, high chronic disease prevalence, and a well-established regulatory framework. Strong physician acceptance of personalized therapeutics and frequent drug shortages further reinforce regional dominance.
Europe
Europe demonstrates stable growth supported by aging populations and expanding HRT utilization. Regulatory harmonization efforts and increasing oversight of sterile compounding practices are shaping market structure, encouraging consolidation and quality standardization.
Asia Pacific
Asia Pacific is poised for accelerated growth due to expanding healthcare access, rising middle-class populations, and increasing awareness of personalized medicine. Cost-sensitive markets and local manufacturing capabilities create opportunities for scalable compounding services.
LAMEA
The LAMEA region is characterized by gradual adoption, driven by improving healthcare infrastructure and increasing demand for specialty formulations. Market growth remains uneven across countries but presents long-term opportunities as regulatory frameworks mature.
Recent Developments
- March 2024: Expansion of sterile compounding facilities by a leading outsourcing pharmacy group to increase hospital contract capacity, strengthening institutional supply reliability.
- September 2023: Strategic partnership between a compounding pharmacy and a specialty pain clinic network to develop customized chronic pain formulations, enhancing therapeutic integration.
- January 2023: Investment in automated quality control and cleanroom technology by a regional compounding provider, improving regulatory compliance and reducing contamination risk.
Critical Business Questions Addressed
- What is the projected value creation trajectory of the global compounding pharmacy market through 2035-
The report quantifies revenue growth and identifies structural drivers underpinning the 5.70% CAGR outlook.
- Which product and therapeutic segments will drive incremental revenue-
Detailed segmentation analysis highlights oral dominance and the emerging potential of sterile parenteral and HRT applications.
- How will regulatory evolution influence competitive positioning-
The study evaluates compliance-driven consolidation and the strategic advantage of high-standard sterile facilities.
- Where should stakeholders prioritize geographic expansion-
Regional analysis identifies North America as mature and Asia Pacific as a high-growth opportunity zone.
- What operational capabilities are critical for long-term competitiveness-
Investment in technology, quality systems, and specialty therapeutic integration emerges as a strategic imperative.
Beyond the Forecast
The compounding pharmacy market is transitioning from a fragmented service niche to a strategically important extension of personalized healthcare delivery. Long-term growth will be defined by regulatory discipline, sterile infrastructure expansion, and therapeutic specialization. Market participants that combine compliance excellence with scalable, technology-enabled operations will be best positioned to capture sustained value in an increasingly patient-centric pharmaceutical ecosystem.


ページTOPに戻る


目次

Table of Contents
Chapter 1. Global Compounding Pharmacy Market Report Scope & Methodology
1.1. Market Definition
1.2. Market Segmentation
1.3. Research Assumption
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.4. Research Objective
1.5. Research Methodology
1.5.1. Forecast Model
1.5.2. Desk Research
1.5.3. Top Down and Bottom-Up Approach
1.6. Research Attributes
1.7. Years Considered for the Study
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Strategic Insights
2.3. Top Findings
2.4. CEO/CXO Standpoint
2.5. ESG Analysis
Chapter 3. Global Compounding Pharmacy Market Forces Analysis
3.1. Market Forces Shaping The Global Compounding Pharmacy Market (2024-2035)
3.2. Drivers
3.2.1. Rising Demand for Personalized Therapeutics
3.2.2. Growth in Chronic Pain and Hormone-Related Conditions
3.2.3. Regulatory Evolution and Compliance Standards
3.3. Restraints
3.3.1. Operational Complexity and Liability Risks
3.3.2. Supply Chain Vulnerabilities and Drug Shortages
3.4. Opportunities
3.4.1. Expansion in Sterile Compounding Capabilities
3.4.2. Specialty Therapeutic Customization
Chapter 4. Global Compounding Pharmacy Industry Analysis
4.1. Porter’s 5 Forces Model
4.2. Porter’s 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
4.4. Macroeconomic Industry Trends
4.4.1. Parent Market Trends
4.4.2. GDP Trends & Forecasts
4.5. Value Chain Analysis
4.6. Top Investment Trends & Forecasts
4.7. Top Winning Strategies (2025)
4.8. Market Share Analysis (2024-2025)
4.9. Pricing Analysis
4.10. Investment & Funding Scenario
4.11. Impact of Geopolitical & Trade Policy Volatility on the Market
Chapter 5. AI Adoption Trends and Market Influence
5.1. AI Readiness Index
5.2. Key Emerging Technologies
5.3. Patent Analysis
5.4. Top Case Studies
Chapter 6. Global Compounding Pharmacy Market Size & Forecasts by Product 2025-2035
6.1. Market Overview
6.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
6.3. Oral
6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
6.3.2. Market size analysis, by region, 2025-2035
6.4. Topical
6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
6.4.2. Market size analysis, by region, 2025-2035
6.5. Parenteral
6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
6.5.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Compounding Pharmacy Market Size & Forecasts by Compounding Type 2025-2035
7.1. Market Overview
7.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
7.3. Ingredient Alteration
7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
7.3.2. Market size analysis, by region, 2025-2035
7.4. Dosage Alteration
7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
7.4.2. Market size analysis, by region, 2025-2035

Chapter 8. Global Compounding Pharmacy Market Size & Forecasts by Therapeutic Application 2025-2035
8.1. Market Overview
8.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
8.3. Pain Management
8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
8.3.2. Market size analysis, by region, 2025-2035
8.4. HRT
8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
8.4.2. Market size analysis, by region, 2025-2035

Chapter 9. Global Compounding Pharmacy Market Size & Forecasts by Sterility2025-2035
9.1. Market Overview
9.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
9.3. Sterile
9.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
9.3.2. Market size analysis, by region, 2025-2035
Chapter 10. Global Compounding Pharmacy Market Size & Forecasts by End User
10.1. Market Overview
10.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
10.3. Pediatirc
10.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
10.3.2. Market size analysis, by region, 2025-2035
10.4. Adult
10.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
10.4.2. Market size analysis, by region, 2025-2035
Chapter 11. Global Compounding Pharmacy Market Size & Forecasts by Region 2025–2035
11.1. Growth Compounding Pharmacy Market, Regional Market Snapshot
11.2. Top Leading & Emerging Countries
11.3. North America Compounding Pharmacy Market
11.3.1. U.S. Compounding Pharmacy Market
11.3.1.1. Product breakdown size & forecasts, 2025-2035
11.3.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.3.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.3.1.4. Sterility breakdown size & forecasts, 2025-2035
11.3.1.5. End User breakdown size & forecasts, 2025-2035
11.3.2. Canada Compounding Pharmacy Market
11.3.2.1. Product breakdown size & forecasts, 2025-2035
11.3.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.3.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.3.2.4. Sterility breakdown size & forecasts, 2025-2035
11.3.2.5. End User breakdown size & forecasts, 2025-2035
11.4. Europe Compounding Pharmacy Market
11.4.1. UK Compounding Pharmacy Market
11.4.1.1. Product breakdown size & forecasts, 2025-2035
11.4.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.1.4. Sterility breakdown size & forecasts, 2025-2035
11.4.1.5. End User breakdown size & forecasts, 2025-2035
11.4.2. Germany Compounding Pharmacy Market
11.4.2.1. Product breakdown size & forecasts, 2025-2035
11.4.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.2.4. Sterility breakdown size & forecasts, 2025-2035
11.4.2.5. End User breakdown size & forecasts, 2025-2035
11.4.3. France Compounding Pharmacy Market
11.4.3.1. Product breakdown size & forecasts, 2025-2035
11.4.3.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.3.4. Sterility breakdown size & forecasts, 2025-2035
11.4.3.5. End User breakdown size & forecasts, 2025-2035
11.4.4. Spain Compounding Pharmacy Market
11.4.4.1. Product breakdown size & forecasts, 2025-2035
11.4.4.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.4.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.4.4. Sterility breakdown size & forecasts, 2025-2035
11.4.4.5. End User breakdown size & forecasts, 2025-2035
11.4.5. Italy Compounding Pharmacy Market
11.4.5.1. Product breakdown size & forecasts, 2025-2035
11.4.5.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.5.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.5.4. Sterility breakdown size & forecasts, 2025-2035
11.4.5.5. End User breakdown size & forecasts, 2025-2035
11.4.6. Rest of Europe Compounding Pharmacy Market
11.4.6.1. Product breakdown size & forecasts, 2025-2035
11.4.6.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.6.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.6.4. Sterility breakdown size & forecasts, 2025-2035
11.4.6.5. End User breakdown size & forecasts, 2025-2035
11.5. Asia Pacific Compounding Pharmacy Market
11.5.1. China Compounding Pharmacy Market
11.5.1.1. Product breakdown size & forecasts, 2025-2035
11.5.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.1.4. Sterility breakdown size & forecasts, 2025-2035
11.5.1.5. End User breakdown size & forecasts, 2025-2035
11.5.2. India Compounding Pharmacy Market
11.5.2.1. Product breakdown size & forecasts, 2025-2035
11.5.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.2.4. Sterility breakdown size & forecasts, 2025-2035
11.5.2.5. End User breakdown size & forecasts, 2025-2035
11.5.3. Japan Compounding Pharmacy Market
11.5.3.1. Product breakdown size & forecasts, 2025-2035
11.5.3.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.3.4. Sterility breakdown size & forecasts, 2025-2035
11.5.3.5. End User breakdown size & forecasts, 2025-2035
11.5.4. Australia Compounding Pharmacy Market
11.5.4.1. Product breakdown size & forecasts, 2025-2035
11.5.4.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.4.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.4.4. Sterility breakdown size & forecasts, 2025-2035
11.5.4.5. End User breakdown size & forecasts, 2025-2035
11.5.5. South Korea Compounding Pharmacy Market
11.5.5.1. Product breakdown size & forecasts, 2025-2035
11.5.5.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.5.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.5.4. Sterility breakdown size & forecasts, 2025-2035
11.5.5.5. End User breakdown size & forecasts, 2025-2035
11.5.6. Rest of APAC Compounding Pharmacy Market
11.5.6.1. Product breakdown size & forecasts, 2025-2035
11.5.6.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.6.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.6.4. Sterility breakdown size & forecasts, 2025-2035
11.5.6.5. End User breakdown size & forecasts, 2025-2035
11.6. Latin America Compounding Pharmacy Market
11.6.1. Brazil Compounding Pharmacy Market
11.6.1.1. Product breakdown size & forecasts, 2025-2035
11.6.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.6.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.6.1.4. Sterility breakdown size & forecasts, 2025-2035
11.6.1.5. End User breakdown size & forecasts, 2025-2035
11.6.2. Mexico Compounding Pharmacy Market
11.6.2.1. Product breakdown size & forecasts, 2025-2035
11.6.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.6.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.6.2.4. Sterility breakdown size & forecasts, 2025-2035
11.6.2.5. End User breakdown size & forecasts, 2025-2035
11.7. Middle East and Africa Compounding Pharmacy Market
11.7.1. UAE Compounding Pharmacy Market
11.7.1.1. Product breakdown size & forecasts, 2025-2035
11.7.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.7.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.7.1.4. Sterility breakdown size & forecasts, 2025-2035
11.7.1.5. End User breakdown size & forecasts, 2025-2035
11.7.2. Saudi Arabia (KSA) Compounding Pharmacy Market
11.7.2.1. Product breakdown size & forecasts, 2025-2035
11.7.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.7.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.7.2.4. Sterility breakdown size & forecasts, 2025-2035
11.7.2.5. End User breakdown size & forecasts, 2025-2035
11.7.3. South Africa Compounding Pharmacy Market
11.7.3.1. Product breakdown size & forecasts, 2025-2035
11.7.3.2. Compounding Type breakdown size & forecasts, 2025-2035
11.7.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.7.3.4. Sterility breakdown size & forecasts, 2025-2035
11.7.3.5. End User breakdown size & forecasts, 2025-2035
Chapter 12. Competitive Intelligence
12.1. Top Market Strategies
12.2. Walgreen Co.
12.2.1. Company Overview
12.2.2. Key Executives
12.2.3. Company Snapshot
12.2.4. Financial Performance (Subject to Data Availability)
12.2.5. Product/Services Port
12.2.6. Recent Development
12.2.7. Market Strategies
12.2.8. SWOT Analysis
12.3. JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy)
12.4. Fagron
12.5. Albertsons Companies
12.6. The London Specialist Pharmacy Ltd (Specialist Pharmacy)
12.7. Galenic Laboratories Limited (Roseway Labs)
12.8. Aurora Compounding
12.9. MEDS Pharmacy
12.10. Apollo Clinical Pharmacy
12.11. Formul8
12.12. Fusion Apothecary

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Compounding Pharmacy Market, Report Scope
Table 2. Global Compounding Pharmacy Market Estimates & Forecasts By Region 2024–2035
Table 3. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 4. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 5. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 6. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 7. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 8. U.S. Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 9. Canada Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 10. UK Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 11. Germany Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 12. France Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 13. Spain Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 14. Italy Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 15. Rest Of Europe Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 16. China Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 17. India Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 18. Japan Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 19. Australia Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 20. South Korea Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
………….

 

ページTOPに戻る


 

Summary

Market Definition, Recent Developments & Industry Trends
The compounding pharmacy market encompasses the customized preparation of medications tailored to the specific needs of individual patients when commercially available drugs are unsuitable. Compounding pharmacies formulate personalized medications by altering dosage strength, combining active ingredients, removing allergens, or modifying dosage forms. The ecosystem comprises independent and hospital-based compounding pharmacies, outsourcing facilities, raw material suppliers, regulatory bodies, and healthcare providers prescribing customized formulations across multiple therapeutic areas.
In recent years, the market has evolved from a largely fragmented, community-based practice to a more regulated and quality-focused industry segment. Heightened regulatory oversight, particularly for sterile compounding, has led to increased compliance investments and operational standardization. Concurrently, growing demand for personalized medicine, hormone replacement therapy (HRT), pediatric formulations, and pain management solutions has expanded the commercial scope of compounding pharmacies. Technology integration in prescription management, quality control systems, and supply chain traceability is further reshaping the industry landscape. Over the forecast period 2025-2035, the market is expected to demonstrate steady growth, supported by demographic shifts, chronic disease prevalence, and the expanding acceptance of individualized therapeutic regimens.
Key Findings of the Report
- Market Size (2024): USD 13.93 billion
- Estimated Market Size (2035): USD 25.63 billion
- CAGR (2025-2035): 5.70%
- Leading Regional Market: North America
- Leading Segment: Oral formulations under Product segment
Market Determinants
Rising Demand for Personalized Therapeutics
The increasing emphasis on patient-centric care models is a primary growth driver. Standardized, mass-produced medications often fail to address specific patient needs such as allergies, dosage sensitivity, or multi-drug compatibility. Compounding pharmacies offer individualized formulations, creating strong value propositions for healthcare providers seeking optimized therapeutic outcomes. This trend directly enhances prescription volumes and long-term customer retention.
Growth in Chronic Pain and Hormone-Related Conditions
The rising incidence of chronic pain disorders and age-related hormonal imbalances is expanding demand for customized pain management and HRT solutions. Patients requiring alternative dosages or delivery formats often rely on compounded medications, reinforcing steady demand within specialized therapeutic segments. As aging populations grow globally, this structural demand driver is expected to sustain long-term market expansion.
Regulatory Evolution and Compliance Standards
Increased regulatory scrutiny, particularly around sterile compounding practices, has reshaped operational frameworks. While stricter compliance raises costs and entry barriers, it also enhances credibility, improves patient safety, and fosters consolidation among established players. High compliance standards create competitive differentiation and reduce risks associated with quality lapses, strengthening institutional trust in compounding services.
Supply Chain Vulnerabilities and Drug Shortages
Frequent drug shortages in commercial pharmaceutical markets have elevated the importance of compounding pharmacies as alternative suppliers. Ingredient alteration and dosage modification capabilities allow rapid response to unavailable formulations. However, dependency on active pharmaceutical ingredient (API) sourcing and fluctuating raw material prices can constrain margins and operational scalability.
Operational Complexity and Liability Risks
Compounding activities, particularly sterile preparations, involve high procedural complexity and stringent quality control requirements. Liability exposure, recall risks, and compliance costs pose challenges to smaller operators. These constraints may limit expansion capacity but also incentivize consolidation and investment in automation and quality management systems.
Opportunity Mapping Based on Market Trends
Expansion in Sterile Compounding Capabilities
Sterile compounding presents significant growth potential as healthcare institutions increasingly outsource complex injectable preparations.
- Investment in advanced cleanroom infrastructure
- Adoption of automated sterile filling systems
- Partnerships with hospital networks
These initiatives position providers to capture higher-margin institutional contracts and reduce contamination risks.
Specialty Therapeutic Customization
Targeted growth in pain management and HRT reflects broader personalization trends.
- Development of niche formulations
- Integration of digital prescription platforms
- Enhanced collaboration with specialty clinics
Such specialization enables differentiation in a competitive landscape and supports premium pricing strategies.
Pediatric and Geriatric Formulation Innovation
Demographic shifts are creating demand for age-appropriate dosage forms.
- Flavor-masked oral suspensions
- Adjusted-dose capsules
- Non-invasive topical applications
Companies investing in patient-friendly delivery systems can strengthen loyalty among pediatric and geriatric segments.
Technology-Driven Quality and Traceability
Digital quality assurance systems and electronic documentation enhance regulatory compliance and operational efficiency.
- Automated batch tracking
- Data-driven compliance audits
- Inventory optimization platforms
Technology adoption not only reduces risk exposure but also supports scalable growth models.
Key Market Segments
By Product:
- Oral
- Topical
- Parenteral
By Compounding Type:
- Ingredient Alteration
- Dosage Alteration
By Therapeutic Application:
- Pain Management
- HRT
By Sterility:
- Sterile
By End User:
- Pediatric
- Adult
Value-Creating Segments and Growth Pockets
Oral formulations currently dominate the market due to their ease of administration, widespread therapeutic applicability, and cost efficiency. However, parenteral products-particularly sterile injectables-are expected to exhibit accelerated growth as hospital outsourcing increases and regulatory compliance standards strengthen.
Within compounding types, dosage alteration remains foundational to everyday compounding activities, while ingredient alteration is gaining momentum due to allergy considerations and combination therapies. In therapeutic applications, pain management holds a substantial share driven by chronic conditions, whereas HRT is projected to grow steadily, supported by aging demographics and increased awareness.
From an end-user perspective, adult patients represent the larger revenue base today, yet pediatric formulations are emerging as a high-growth pocket given the lack of commercially available child-specific dosages and delivery formats.
Regional Market Assessment
North America
North America leads the global compounding pharmacy market, driven by advanced healthcare infrastructure, high chronic disease prevalence, and a well-established regulatory framework. Strong physician acceptance of personalized therapeutics and frequent drug shortages further reinforce regional dominance.
Europe
Europe demonstrates stable growth supported by aging populations and expanding HRT utilization. Regulatory harmonization efforts and increasing oversight of sterile compounding practices are shaping market structure, encouraging consolidation and quality standardization.
Asia Pacific
Asia Pacific is poised for accelerated growth due to expanding healthcare access, rising middle-class populations, and increasing awareness of personalized medicine. Cost-sensitive markets and local manufacturing capabilities create opportunities for scalable compounding services.
LAMEA
The LAMEA region is characterized by gradual adoption, driven by improving healthcare infrastructure and increasing demand for specialty formulations. Market growth remains uneven across countries but presents long-term opportunities as regulatory frameworks mature.
Recent Developments
- March 2024: Expansion of sterile compounding facilities by a leading outsourcing pharmacy group to increase hospital contract capacity, strengthening institutional supply reliability.
- September 2023: Strategic partnership between a compounding pharmacy and a specialty pain clinic network to develop customized chronic pain formulations, enhancing therapeutic integration.
- January 2023: Investment in automated quality control and cleanroom technology by a regional compounding provider, improving regulatory compliance and reducing contamination risk.
Critical Business Questions Addressed
- What is the projected value creation trajectory of the global compounding pharmacy market through 2035-
The report quantifies revenue growth and identifies structural drivers underpinning the 5.70% CAGR outlook.
- Which product and therapeutic segments will drive incremental revenue-
Detailed segmentation analysis highlights oral dominance and the emerging potential of sterile parenteral and HRT applications.
- How will regulatory evolution influence competitive positioning-
The study evaluates compliance-driven consolidation and the strategic advantage of high-standard sterile facilities.
- Where should stakeholders prioritize geographic expansion-
Regional analysis identifies North America as mature and Asia Pacific as a high-growth opportunity zone.
- What operational capabilities are critical for long-term competitiveness-
Investment in technology, quality systems, and specialty therapeutic integration emerges as a strategic imperative.
Beyond the Forecast
The compounding pharmacy market is transitioning from a fragmented service niche to a strategically important extension of personalized healthcare delivery. Long-term growth will be defined by regulatory discipline, sterile infrastructure expansion, and therapeutic specialization. Market participants that combine compliance excellence with scalable, technology-enabled operations will be best positioned to capture sustained value in an increasingly patient-centric pharmaceutical ecosystem.


ページTOPに戻る


Table of Contents

Table of Contents
Chapter 1. Global Compounding Pharmacy Market Report Scope & Methodology
1.1. Market Definition
1.2. Market Segmentation
1.3. Research Assumption
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.4. Research Objective
1.5. Research Methodology
1.5.1. Forecast Model
1.5.2. Desk Research
1.5.3. Top Down and Bottom-Up Approach
1.6. Research Attributes
1.7. Years Considered for the Study
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Strategic Insights
2.3. Top Findings
2.4. CEO/CXO Standpoint
2.5. ESG Analysis
Chapter 3. Global Compounding Pharmacy Market Forces Analysis
3.1. Market Forces Shaping The Global Compounding Pharmacy Market (2024-2035)
3.2. Drivers
3.2.1. Rising Demand for Personalized Therapeutics
3.2.2. Growth in Chronic Pain and Hormone-Related Conditions
3.2.3. Regulatory Evolution and Compliance Standards
3.3. Restraints
3.3.1. Operational Complexity and Liability Risks
3.3.2. Supply Chain Vulnerabilities and Drug Shortages
3.4. Opportunities
3.4.1. Expansion in Sterile Compounding Capabilities
3.4.2. Specialty Therapeutic Customization
Chapter 4. Global Compounding Pharmacy Industry Analysis
4.1. Porter’s 5 Forces Model
4.2. Porter’s 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
4.4. Macroeconomic Industry Trends
4.4.1. Parent Market Trends
4.4.2. GDP Trends & Forecasts
4.5. Value Chain Analysis
4.6. Top Investment Trends & Forecasts
4.7. Top Winning Strategies (2025)
4.8. Market Share Analysis (2024-2025)
4.9. Pricing Analysis
4.10. Investment & Funding Scenario
4.11. Impact of Geopolitical & Trade Policy Volatility on the Market
Chapter 5. AI Adoption Trends and Market Influence
5.1. AI Readiness Index
5.2. Key Emerging Technologies
5.3. Patent Analysis
5.4. Top Case Studies
Chapter 6. Global Compounding Pharmacy Market Size & Forecasts by Product 2025-2035
6.1. Market Overview
6.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
6.3. Oral
6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
6.3.2. Market size analysis, by region, 2025-2035
6.4. Topical
6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
6.4.2. Market size analysis, by region, 2025-2035
6.5. Parenteral
6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
6.5.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Compounding Pharmacy Market Size & Forecasts by Compounding Type 2025-2035
7.1. Market Overview
7.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
7.3. Ingredient Alteration
7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
7.3.2. Market size analysis, by region, 2025-2035
7.4. Dosage Alteration
7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
7.4.2. Market size analysis, by region, 2025-2035

Chapter 8. Global Compounding Pharmacy Market Size & Forecasts by Therapeutic Application 2025-2035
8.1. Market Overview
8.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
8.3. Pain Management
8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
8.3.2. Market size analysis, by region, 2025-2035
8.4. HRT
8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
8.4.2. Market size analysis, by region, 2025-2035

Chapter 9. Global Compounding Pharmacy Market Size & Forecasts by Sterility2025-2035
9.1. Market Overview
9.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
9.3. Sterile
9.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
9.3.2. Market size analysis, by region, 2025-2035
Chapter 10. Global Compounding Pharmacy Market Size & Forecasts by End User
10.1. Market Overview
10.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025)
10.3. Pediatirc
10.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
10.3.2. Market size analysis, by region, 2025-2035
10.4. Adult
10.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
10.4.2. Market size analysis, by region, 2025-2035
Chapter 11. Global Compounding Pharmacy Market Size & Forecasts by Region 2025–2035
11.1. Growth Compounding Pharmacy Market, Regional Market Snapshot
11.2. Top Leading & Emerging Countries
11.3. North America Compounding Pharmacy Market
11.3.1. U.S. Compounding Pharmacy Market
11.3.1.1. Product breakdown size & forecasts, 2025-2035
11.3.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.3.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.3.1.4. Sterility breakdown size & forecasts, 2025-2035
11.3.1.5. End User breakdown size & forecasts, 2025-2035
11.3.2. Canada Compounding Pharmacy Market
11.3.2.1. Product breakdown size & forecasts, 2025-2035
11.3.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.3.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.3.2.4. Sterility breakdown size & forecasts, 2025-2035
11.3.2.5. End User breakdown size & forecasts, 2025-2035
11.4. Europe Compounding Pharmacy Market
11.4.1. UK Compounding Pharmacy Market
11.4.1.1. Product breakdown size & forecasts, 2025-2035
11.4.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.1.4. Sterility breakdown size & forecasts, 2025-2035
11.4.1.5. End User breakdown size & forecasts, 2025-2035
11.4.2. Germany Compounding Pharmacy Market
11.4.2.1. Product breakdown size & forecasts, 2025-2035
11.4.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.2.4. Sterility breakdown size & forecasts, 2025-2035
11.4.2.5. End User breakdown size & forecasts, 2025-2035
11.4.3. France Compounding Pharmacy Market
11.4.3.1. Product breakdown size & forecasts, 2025-2035
11.4.3.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.3.4. Sterility breakdown size & forecasts, 2025-2035
11.4.3.5. End User breakdown size & forecasts, 2025-2035
11.4.4. Spain Compounding Pharmacy Market
11.4.4.1. Product breakdown size & forecasts, 2025-2035
11.4.4.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.4.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.4.4. Sterility breakdown size & forecasts, 2025-2035
11.4.4.5. End User breakdown size & forecasts, 2025-2035
11.4.5. Italy Compounding Pharmacy Market
11.4.5.1. Product breakdown size & forecasts, 2025-2035
11.4.5.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.5.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.5.4. Sterility breakdown size & forecasts, 2025-2035
11.4.5.5. End User breakdown size & forecasts, 2025-2035
11.4.6. Rest of Europe Compounding Pharmacy Market
11.4.6.1. Product breakdown size & forecasts, 2025-2035
11.4.6.2. Compounding Type breakdown size & forecasts, 2025-2035
11.4.6.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.4.6.4. Sterility breakdown size & forecasts, 2025-2035
11.4.6.5. End User breakdown size & forecasts, 2025-2035
11.5. Asia Pacific Compounding Pharmacy Market
11.5.1. China Compounding Pharmacy Market
11.5.1.1. Product breakdown size & forecasts, 2025-2035
11.5.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.1.4. Sterility breakdown size & forecasts, 2025-2035
11.5.1.5. End User breakdown size & forecasts, 2025-2035
11.5.2. India Compounding Pharmacy Market
11.5.2.1. Product breakdown size & forecasts, 2025-2035
11.5.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.2.4. Sterility breakdown size & forecasts, 2025-2035
11.5.2.5. End User breakdown size & forecasts, 2025-2035
11.5.3. Japan Compounding Pharmacy Market
11.5.3.1. Product breakdown size & forecasts, 2025-2035
11.5.3.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.3.4. Sterility breakdown size & forecasts, 2025-2035
11.5.3.5. End User breakdown size & forecasts, 2025-2035
11.5.4. Australia Compounding Pharmacy Market
11.5.4.1. Product breakdown size & forecasts, 2025-2035
11.5.4.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.4.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.4.4. Sterility breakdown size & forecasts, 2025-2035
11.5.4.5. End User breakdown size & forecasts, 2025-2035
11.5.5. South Korea Compounding Pharmacy Market
11.5.5.1. Product breakdown size & forecasts, 2025-2035
11.5.5.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.5.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.5.4. Sterility breakdown size & forecasts, 2025-2035
11.5.5.5. End User breakdown size & forecasts, 2025-2035
11.5.6. Rest of APAC Compounding Pharmacy Market
11.5.6.1. Product breakdown size & forecasts, 2025-2035
11.5.6.2. Compounding Type breakdown size & forecasts, 2025-2035
11.5.6.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.5.6.4. Sterility breakdown size & forecasts, 2025-2035
11.5.6.5. End User breakdown size & forecasts, 2025-2035
11.6. Latin America Compounding Pharmacy Market
11.6.1. Brazil Compounding Pharmacy Market
11.6.1.1. Product breakdown size & forecasts, 2025-2035
11.6.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.6.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.6.1.4. Sterility breakdown size & forecasts, 2025-2035
11.6.1.5. End User breakdown size & forecasts, 2025-2035
11.6.2. Mexico Compounding Pharmacy Market
11.6.2.1. Product breakdown size & forecasts, 2025-2035
11.6.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.6.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.6.2.4. Sterility breakdown size & forecasts, 2025-2035
11.6.2.5. End User breakdown size & forecasts, 2025-2035
11.7. Middle East and Africa Compounding Pharmacy Market
11.7.1. UAE Compounding Pharmacy Market
11.7.1.1. Product breakdown size & forecasts, 2025-2035
11.7.1.2. Compounding Type breakdown size & forecasts, 2025-2035
11.7.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.7.1.4. Sterility breakdown size & forecasts, 2025-2035
11.7.1.5. End User breakdown size & forecasts, 2025-2035
11.7.2. Saudi Arabia (KSA) Compounding Pharmacy Market
11.7.2.1. Product breakdown size & forecasts, 2025-2035
11.7.2.2. Compounding Type breakdown size & forecasts, 2025-2035
11.7.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.7.2.4. Sterility breakdown size & forecasts, 2025-2035
11.7.2.5. End User breakdown size & forecasts, 2025-2035
11.7.3. South Africa Compounding Pharmacy Market
11.7.3.1. Product breakdown size & forecasts, 2025-2035
11.7.3.2. Compounding Type breakdown size & forecasts, 2025-2035
11.7.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035
11.7.3.4. Sterility breakdown size & forecasts, 2025-2035
11.7.3.5. End User breakdown size & forecasts, 2025-2035
Chapter 12. Competitive Intelligence
12.1. Top Market Strategies
12.2. Walgreen Co.
12.2.1. Company Overview
12.2.2. Key Executives
12.2.3. Company Snapshot
12.2.4. Financial Performance (Subject to Data Availability)
12.2.5. Product/Services Port
12.2.6. Recent Development
12.2.7. Market Strategies
12.2.8. SWOT Analysis
12.3. JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy)
12.4. Fagron
12.5. Albertsons Companies
12.6. The London Specialist Pharmacy Ltd (Specialist Pharmacy)
12.7. Galenic Laboratories Limited (Roseway Labs)
12.8. Aurora Compounding
12.9. MEDS Pharmacy
12.10. Apollo Clinical Pharmacy
12.11. Formul8
12.12. Fusion Apothecary

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Compounding Pharmacy Market, Report Scope
Table 2. Global Compounding Pharmacy Market Estimates & Forecasts By Region 2024–2035
Table 3. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 4. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 5. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 6. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 7. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035
Table 8. U.S. Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 9. Canada Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 10. UK Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 11. Germany Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 12. France Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 13. Spain Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 14. Italy Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 15. Rest Of Europe Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 16. China Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 17. India Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 18. Japan Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 19. Australia Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
Table 20. South Korea Compounding Pharmacy Market Estimates & Forecasts, 2024–2035
………….

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Bizwit Research & Consulting LLP社の 医療・ライフサイエンス分野 での最新刊レポート

本レポートと同じKEY WORD(pharmacy)の最新刊レポート


よくあるご質問


Bizwit Research & Consulting LLP社はどのような調査会社ですか?


Bizwit Research & Consulting (Bizwit Research & Consulting LLP)は世界の多様なマクロおよびマイクロ経済の動向を継続的に調査しています。 ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/04/10 10:27

160.30 円

187.66 円

217.84 円

ページTOPに戻る